Non-Alcoholic Fatty Liver Disease Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Pfizer, Eli Lilly and Company, CohBar, Inc., Roche, Amgen

Posted on
by

Non-Alcoholic Fatty Liver Disease Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Pfizer, Eli Lilly and Company, CohBar, Inc., Roche, Amgen
The Non-Alcoholic Fatty Liver Disease Market Forecast report offers an in-depth understanding of the Non-Alcoholic Fatty Liver Disease, historical and forecasted epidemiology as well as the Non-Alcoholic Fatty Liver Disease market trends in the 7MM.

DelveInsight’s “Non-Alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Non-Alcoholic Fatty Liver Disease, historical and forecasted epidemiology as well as the Non-Alcoholic Fatty Liver Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Non-Alcoholic Fatty Liver Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Alcoholic Fatty Liver Disease Market Forecast

 

Some of the key facts of the Non-Alcoholic Fatty Liver Disease Market Report: 

  • The Non-Alcoholic Fatty Liver Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In September 2022, Inventiva and Chia Tai-Tianqing Pharmaceutical Group entered into a licensing and collaboration agreement to develop and commercialize lanifibranor, if approved, for the treatment of nonalcoholic steatohepatitis and potentially other metabolic diseases in mainland China, Hong Kong, Macau, and Taiwan
  • In May 2022, Hepion Pharmaceuticals entered into a clinical collaboration with HepQuant, a Denver-based, privately held company with novel, proprietary investigational technology for evaluating liver function and health in patients with chronic liver diseases. Hepion will incorporate the HepQuant ‘’SHUNT’’ test into a dedicated Phase IIb clinical trial in presumed NASH F3 subjects, initiating in Q3 of this year
  • In January 2022, LISCure Biosciences entered into a research collaboration agreement with Mayo Clinic for new drug development for rare liver diseases
  • The existing pipeline for NASH comprises a wide array of medications. FXR agonists, FGF21 stimulants, FGF19 analogs, glucagon-like peptide-1 (GLP-1) agonists, peroxisome proliferator-activated receptor (PPAR) regulators, THR-β agonists, and several others are among the prominent classes for this condition.
  • According to American Liver Foundation (n.d.), NAFLD is the most common chronic liver condition in the United States. It’s estimated that about 25% of adults in the U.S. have NAFLD. Of those with NAFLD, about 20% have NASH (5% of adults in the US). Most people with NAFLD have simply fatty live
  • According to the study conducted by Foschi et al. (2019), titled, “Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study,” the prevalence of non-alcoholic fatty liver disease (NAFLD) was 0.46 (0.41 to 0.51) vs. 0.22 (0.21 to 0.24) in citizens with than in those without altered liver enzymes
  • Key Non-Alcoholic Fatty Liver Disease Companies: Inventiva Pharma, Eli Lilly and Company, Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, 89bio, Inc., Novo Nordisk A/S, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, J2H Biotech, Haisco Pharmaceutical, Madrigal Pharmaceuticals, Altimmune, Inc., GlaxoSmithKline, Axcella Health, Inc, AstraZeneca, Gannex Pharma Co., Ltd., Dexa Medica Group, Boehringer Ingelheim, Can-Fite BioPharma, Rivus Pharmaceuticals, Inc., Regeneron Pharmaceuticals, MediciNova, and others
  • Key Non-Alcoholic Fatty Liver Disease Therapies: Lanifibranor, Tirzepatide, MGL-3196, Semaglutide, Obeticholicacid (OCA), Pegozafermin, DA-1241, NNC0194 0499, J2H-1702, HSK31679, Resmetirom, Pemvidutide, GSK4532990, AXA1125, AZD9550, 2mg of ASC41, Proliverenol, Survodutide, Namodenoson, HU6, ALN-HSD, MN-001, and others
  • The Non-Alcoholic Fatty Liver Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Alcoholic Fatty Liver Disease pipeline products will significantly revolutionize the Non-Alcoholic Fatty Liver Disease market dynamics.

 

Non-Alcoholic Fatty Liver Disease Overview

Non-alcoholic fatty liver disease (NAFLD) is an umbrella term that encompasses the entire spectrum of fatty liver disease, from simple steatosis to more progressive steatosis with associated hepatitis, fibrosis, cirrhosis, and in some cases hepatocellular carcinoma.

 

Get a Free sample for the Non-Alcoholic Fatty Liver Disease Market Report –

https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-market

 

Non-Alcoholic Fatty Liver Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Non-Alcoholic Fatty Liver Disease Epidemiology Segmentation:

The Non-Alcoholic Fatty Liver Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Non-Alcoholic Fatty Liver Disease
  • Prevalent Cases of Non-Alcoholic Fatty Liver Disease by severity
  • Gender-specific Prevalence of Non-Alcoholic Fatty Liver Disease
  • Diagnosed Cases of Episodic and Chronic Non-Alcoholic Fatty Liver Disease

 

Download the report to understand which factors are driving Non-Alcoholic Fatty Liver Disease epidemiology trends @ Non-Alcoholic Fatty Liver Disease Epidemiology Forecast

 

Non-Alcoholic Fatty Liver Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Alcoholic Fatty Liver Disease market or expected to get launched during the study period. The analysis covers Non-Alcoholic Fatty Liver Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Non-Alcoholic Fatty Liver Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Non-Alcoholic Fatty Liver Disease Therapies and Key Companies

  • Lanifibranor: Inventiva Pharma
  • Tirzepatide: Eli Lilly and Company
  • MGL-3196: Madrigal Pharmaceuticals, Inc.
  • Obeticholicacid (OCA): Intercept Pharmaceuticals
  • Pegozafermin: 89bio, Inc.
  • Semaglutide: Novo Nordisk A/S
  • DA-1241: NeuroBo Pharmaceuticals Inc
  • NNC0194 0499: Novo Nordisk A/S
  • J2H-1702: J2H Biotech
  • HSK31679: Haisco Pharmaceutical
  • Resmetirom: Madrigal Pharmaceuticals
  • Pemvidutide: Altimmune, Inc.
  • GSK4532990: GlaxoSmithKline
  • AXA1125: Axcella Health, Inc
  • AZD9550: AstraZeneca
  • 2mg of ASC41: Gannex Pharma Co., Ltd.
  • Proliverenol: Dexa Medica Group
  • Survodutide: Boehringer Ingelheim
  • Namodenoson: Can-Fite BioPharma
  • HU6: Rivus Pharmaceuticals, Inc.
  • ALN-HSD: Regeneron Pharmaceuticals
  • MN-001: MediciNova

 

Discover more about therapies set to grab major Non-Alcoholic Fatty Liver Disease market share @ Non-Alcoholic Fatty Liver Disease Treatment Market

 

Non-Alcoholic Fatty Liver Disease Market Strengths

  • Growing research activities and multiple clinical trials ongoing for NASH, suggests that the number of drugs is being developed, that will strengthen the market

 

Non-Alcoholic Fatty Liver Disease Market Opportunities

  • Lucrative opportunities for the market growth in United States, owing to presence of large pool of patients suffering from NASH

 

Scope of the Non-Alcoholic Fatty Liver Disease Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Non-Alcoholic Fatty Liver Disease Companies: Inventiva Pharma, Eli Lilly and Company, Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, 89bio, Inc., Novo Nordisk A/S, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, J2H Biotech, Haisco Pharmaceutical, Madrigal Pharmaceuticals, Altimmune, Inc., GlaxoSmithKline, Axcella Health, Inc, AstraZeneca, Gannex Pharma Co., Ltd., Dexa Medica Group, Boehringer Ingelheim, Can-Fite BioPharma, Rivus Pharmaceuticals, Inc., Regeneron Pharmaceuticals, MediciNova, and others
  • Key Non-Alcoholic Fatty Liver Disease Therapies: Lanifibranor, Tirzepatide, MGL-3196, Semaglutide, Obeticholicacid (OCA), Pegozafermin, DA-1241, NNC0194 0499, J2H-1702, HSK31679, Resmetirom, Pemvidutide, GSK4532990, AXA1125, AZD9550, 2mg of ASC41, Proliverenol, Survodutide, Namodenoson, HU6, ALN-HSD, MN-001, and others
  • Non-Alcoholic Fatty Liver Disease Therapeutic Assessment: Non-Alcoholic Fatty Liver Disease current marketed and Non-Alcoholic Fatty Liver Disease emerging therapies
  • Non-Alcoholic Fatty Liver Disease Market Dynamics: Non-Alcoholic Fatty Liver Disease market drivers and Non-Alcoholic Fatty Liver Disease market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Non-Alcoholic Fatty Liver Disease Unmet Needs, KOL’s views, Analyst’s views, Non-Alcoholic Fatty Liver Disease Market Access and Reimbursement 

 

To know more about Non-Alcoholic Fatty Liver Disease companies working in the treatment market, visit @ Non-Alcoholic Fatty Liver Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Non-Alcoholic Fatty Liver Disease Market Report Introduction

2. Executive Summary for Non-Alcoholic Fatty Liver Disease

3. SWOT analysis of Non-Alcoholic Fatty Liver Disease

4. Non-Alcoholic Fatty Liver Disease Patient Share (%) Overview at a Glance

5. Non-Alcoholic Fatty Liver Disease Market Overview at a Glance

6. Non-Alcoholic Fatty Liver Disease Disease Background and Overview

7. Non-Alcoholic Fatty Liver Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Non-Alcoholic Fatty Liver Disease 

9. Non-Alcoholic Fatty Liver Disease Current Treatment and Medical Practices

10. Non-Alcoholic Fatty Liver Disease Unmet Needs

11. Non-Alcoholic Fatty Liver Disease Emerging Therapies

12. Non-Alcoholic Fatty Liver Disease Market Outlook

13. Country-Wise Non-Alcoholic Fatty Liver Disease Market Analysis (2019–2032)

14. Non-Alcoholic Fatty Liver Disease Market Access and Reimbursement of Therapies

15. Non-Alcoholic Fatty Liver Disease Market Drivers

16. Non-Alcoholic Fatty Liver Disease Market Barriers

17.  Non-Alcoholic Fatty Liver Disease Appendix

18. Non-Alcoholic Fatty Liver Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/